Soligenix, Inc. — 2014 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2014, and compares results with 2013. Soligenix is a development-stage biopharmaceutical company with BioTherapeutics and Vaccines/BioDefense segments. It had no approved products and no significant product-sale revenue; reported revenue came primarily from government grants and contracts.
Financial performance and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $7.04 million | $3.22 million |
| Cost of revenue | $5.31 million | $2.54 million |
| Gross profit and margin | $1.73 million; 24.6% | $0.68 million; 21.1% |
| Operating loss | $10.76 million | $7.16 million |
| Net loss | $6.71 million | $10.06 million |
| Net cash used in operating activities | $2.47 million | $4.46 million |
| Cash and cash equivalents at year-end | $5.53 million | $5.86 million |
- Revenue increased 118%, principally from BARDA/NIAID-funded OrbeShield work and the start of RiVax contract activity. Vaccines/BioDefense revenue was $6.76 million; BioTherapeutics revenue was $0.29 million.
- Gross profit rose 154%; management attributed the increase to government contracts that include management fees and overhead reimbursement.
- The net loss narrowed despite a larger operating loss. Results included a non-cash $3.44 million gain from remeasuring warrant liabilities, versus a $3.65 million non-cash expense in 2013, and a $0.62 million state tax benefit from selling New Jersey net operating losses.
- Research and development expense, including $4.00 million of acquired in-process R&D for SGX301, was $9.09 million versus $5.07 million in 2013. The income statement presents this as $5.09 million of R&D plus $4.00 million of acquired in-process R&D.
- Operating cash use was partly offset by $2.44 million of financing proceeds, including a December public offering and Lincoln Park equity-facility sales. No conventional debt balance is listed on the balance sheet; current liabilities included accounts payable, warrant liability and accrued compensation.
- Year-end current assets were $6.49 million and current liabilities were $7.11 million, including a $3.79 million non-cash warrant liability. Management reported working capital of $3.17 million excluding that warrant liability; without the exclusion, current liabilities exceeded current assets by approximately $0.62 million.
Material changes and business developments
- Soligenix acquired the SGX301 synthetic-hypericin assets in 2014 for $250,000 cash and 1,849,113 shares valued at $3.75 million; the total $4.00 million was expensed as acquired in-process R&D. Additional milestone payments of up to $10 million may be due in restricted shares if specified milestones are met.
- Common shares outstanding increased from 19.63 million at year-end 2013 to 23.94 million at year-end 2014, reflecting financing, acquisition-related and other share issuances. The company had 25.17 million shares outstanding as of March 17, 2015.
- BioTherapeutics operating loss increased to $7.67 million from $3.07 million, mainly due to the SGX301 acquisition and continued SGX942 Phase 2 work. Vaccines/BioDefense reported $0.81 million of operating income, compared with a $1.67 million operating loss in 2013, supported by contract margins.
Outlook, risks and contingencies
- Management expected available cash, government contract and grant proceeds, the Lincoln Park equity facility and potential New Jersey NOL-sale proceeds to fund operations for at least 12 months. It forecast approximately $16.0 million of R&D expenditure over the next 12 months, including an estimated $10.1 million of government reimbursements. The forecast depends on funding, reimbursements and access to financing; management also said it may seek additional equity financing.
- The company cited up to $51.4 million of active contract and grant funding available for associated programs, but some awards depend on government options and continued funding. The NIAID RiVax contract could provide up to $24.7 million and BARDA/NIAID OrbeShield contracts up to $32.7 million if options are exercised.
- Planned development milestones included Phase 3 trials for SGX301 and SGX203, both anticipated to start in 2015; SGX942 Phase 2 data expected in the second half of 2015; and continued preclinical and manufacturing work on biodefense candidates. Timelines and outcomes are uncertain.
- Key risks include recurring losses, the need for further financing and potential shareholder dilution; clinical and regulatory failure or delay; dependence on government funding and procurement; reliance on single-source manufacturers and other third parties; competition; and limited commercialization capabilities. The prior Phase 3 orBec trial for acute GI GVHD was stopped in 2011 after a monitoring board concluded it was highly unlikely to meet its efficacy endpoint; that program was terminated.
- Future obligations include approximately $375,000 of licensing commitments and up to $7.9 million of contingent license and collaboration milestones, plus potential SGX301 milestones of up to $10 million. The company also disclosed possible royalties of up to 6% on covered product sales. These contingent amounts depend on clinical or commercial success.
Most important facts for investors to verify
- Cash runway: test management’s 12-month liquidity outlook against actual cash burn, grant reimbursements, contract-option exercise and equity-facility availability.
- Clinical execution: confirm trial starts, enrollment and readouts for SGX301, SGX203 and SGX942, and assess results against the stated timelines.
- Funding quality: distinguish awarded base-period funding from optional or contingent contract amounts, and confirm government priorities and continued program support.
- Dilution and warrant accounting: review share issuance, the remaining Lincoln Park facility, outstanding warrants and options, and the effect of the non-cash warrant remeasurement on reported earnings.
- Financial reporting: the auditor issued an unqualified opinion on the financial statements. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor was not engaged to express an opinion on internal control effectiveness.